Devyser Diagnostics AB has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is valid for a period of up to four years. Indicative order value is estimated to be approximately SEK 2.5 million annually.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
99.8 SEK | +0.81% | -0.20% | +26.97% |
05-08 | Transcript : Devyser Diagnostics AB, Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Devyser Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.97% | 148M | |
+18.48% | 47.02B | |
+48.77% | 41.86B | |
+0.51% | 41.76B | |
-4.27% | 28.8B | |
+11.85% | 26.05B | |
-22.17% | 19.15B | |
+4.65% | 12.55B | |
+29.83% | 12.34B | |
-3.91% | 11.82B |
- Stock Market
- Equities
- DVYSR Stock
- News Devyser Diagnostics AB
- Devyser Diagnostics AB Achieves Breakthrough in the US with Cystic Fibrosis NGS Test